Tonix Pharmaceuticals Launches Phase 2 Trial for Acute Stress Reaction Treatment
Tonix Pharmaceuticals has initiated a Department of Defense-backed clinical trial to evaluate TNX-102 SL as a potential treatment for acute stress reaction in motor vehicle trauma survivors, addressing a critical need in mental health care.
Tonix Pharmaceuticals has begun a Phase 2 clinical trial targeting acute stress reaction (ASR) treatment, with the first patient enrolled in the OASIS study. The trial, sponsored by the University of North Carolina's Institute for Trauma Recovery and supported by a $3 million U.S. Department of Defense grant, aims to evaluate TNX-102 SL's effectiveness in reducing ASR severity and preventing acute stress disorder.
The study will recruit approximately 180 motor vehicle trauma survivors across emergency departments nationwide. TNX-102 SL has previously demonstrated potential improvements in sleep and early PTSD symptoms, which are considered critical factors in mitigating acute stress reactions.
CEO Dr. Seth Lederman highlighted the urgent need for treatments addressing trauma-induced stress in both civilian and military populations. The research represents a significant step toward developing targeted interventions for individuals experiencing immediate psychological responses to traumatic events.
Researchers expect to obtain topline data in the second half of 2026, potentially offering new insights into managing acute stress reactions. The trial's outcomes could have substantial implications for mental health treatment protocols, particularly for individuals who have experienced sudden, severe psychological trauma.